Language:

Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction

International journal of molecular sciences, 2017-06, Vol.18 (6), p.1321 [Peer Reviewed Journal]

2017. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2017 by the authors. 2017 ;ISSN: 1422-0067 ;ISSN: 1661-6596 ;EISSN: 1422-0067 ;DOI: 10.3390/ijms18061321 ;PMID: 28635626

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction
Author: Achari, Arunkumar E ; Jain, Sushil K
Subjects: Adipocytes ; Adiponectin ; Adiponectin - analysis ; Adiponectin - metabolism ; Adiponectin - therapeutic use ; Amino acids ; Anaerobic threshold ; Animals ; Arteriosclerosis ; Atherosclerosis ; Biosynthesis ; Body fat ; Body weight ; Bone density ; Cardiomyocytes ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - metabolism ; Cardiovascular Diseases - pathology ; Chemical bonds ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Diabetes Mellitus, Type 2 - pathology ; Diabetic retinopathy ; Disease resistance ; Endoplasmic reticulum ; Endothelial cells ; Endothelium - drug effects ; Endothelium - metabolism ; Endothelium - pathology ; Exercise ; Fibroblasts ; Humans ; Hypertension ; Inflammation ; Insulin ; Insulin Resistance ; Isoforms ; Kinases ; Lipids ; Metabolic syndrome ; Models, Molecular ; Molecular Targeted Therapy ; Molecular weight ; Muscles ; Myocytes ; Obesity ; Obesity - drug therapy ; Obesity - metabolism ; Obesity - pathology ; Oxidoreductase ; Proteins ; Review ; Rodents ; Secretion ; Sensitizing ; Signal transduction ; Signal Transduction - drug effects ; Skeletal muscle ; Systematic review ; Therapeutic applications ; Therapeutic targets
Is Part Of: International journal of molecular sciences, 2017-06, Vol.18 (6), p.1321
Description: Adiponectin is the most abundant peptide secreted by adipocytes, whose reduction plays a central role in obesity-related diseases, including insulin resistance/type 2 diabetes and cardiovascular disease. In addition to adipocytes, other cell types, such as skeletal and cardiac myocytes and endothelial cells, can also produce this adipocytokine. Adiponectin effects are mediated by adiponectin receptors, which occur as two isoforms (AdipoR1 and AdipoR2). Adiponectin has direct actions in liver, skeletal muscle, and the vasculature.Adiponectin exists in the circulation as varying molecular weight forms, produced by multimerization. Several endoplasmic reticulum ER-associated proteins, including ER oxidoreductase 1-α (Ero1-α), ER resident protein 44 (ERp44), disulfide-bond A oxidoreductase-like protein (DsbA-L), and glucose-regulated protein 94 (GPR94), have recently been found to be involved in the assembly and secretion of higher-order adiponectin complexes. Recent data indicate that the high-molecular weight (HMW) complexes have the predominant action in metabolic tissues. Studies have shown that adiponectin administration in humans and rodents has insulin-sensitizing, anti-atherogenic, and anti-inflammatory effects, and, in certain settings, also decreases body weight. Therefore, adiponectin replacement therapy in humans may suggest potential versatile therapeutic targets in the treatment of obesity, insulin resistance/type 2 diabetes, and atherosclerosis. The current knowledge on regulation and function of adiponectin in obesity, insulin resistance, and cardiovascular disease is summarized in this review.
Publisher: Switzerland: MDPI AG
Language: English
Identifier: ISSN: 1422-0067
ISSN: 1661-6596
EISSN: 1422-0067
DOI: 10.3390/ijms18061321
PMID: 28635626
Source: MEDLINE
PubMed Central
ProQuest Central
DOAJ Directory of Open Access Journals

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction

Searching Remote Databases, Please Wait